The effect of protein kinase C inhibition on renal and peripheral hemodynamic function in patients with type 1 diabetes mellitus
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 17 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2006 New trial record.